Omics data strategy, precision medicine and modern biotechnology revolution

The biopharmaceutical industry has quickly entered an era when fast evolving multidisciplinary omics technologies, historical precision medicine initiatives and disruptive bioinformatics techniques synergistically start to provide pivotal and strategic support for new drug development. Unprecedented amount of data is being generated to help discover and develop new generations of medications. Using examples, this talk covers several of the most important bioinformatic considerations in this strategy which includes: How do we efficiently manage the massive amount of data at different levels of precision to ensure a seamless data flow? How do we annotate and present these data to make it more comprehensible and deliverable? How do we design and execute the new clinical trials more efficiently and improve the success rate? Where are we and where are we going in this new precision medicine era?

Biography
Dongliang Ge is the President at BioSciKin Co., Ltd., and former Director of Bioinformatics at Gilead Sciences. He was appointed as an Assistant Professor at Duke University, USA. He has completed his PhD in Biostatistics and Genetic Epidemiology at Chinese Academy of Medical Sciences in 2004. His work in the IL28B genetic variants, published in Nature in 2009, has received over 3000 citations to date. In total, his work has received over 15,000 citations.

gedongliang@bioscikin.com